Excipient Market Overview: Clariant sets up its first PEG excipients facility in US; India harmonizes 22 excipient monographs

DATA COMPILATION
#PharmaFlow

Pipeline Prospector February 2026 highlights: Gilead buys Arcellx for US$ 7.8 bn; FDA okays Vanda’s psychotic pill

Stock Recap
#PipelineProspector

Roximycin

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

45 API Suppliers, 21 USDMF, 11 CEP/COS, 1 JDMF, 2 EU WC, 2 KDMF, 13 NDC API, 1 VMF, 20 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

44 Drugs in Development

44 Drugs in Development

FINISHED DOSAGE FORMULATIONS

269 FDF Dossiers, 191 FDA Orange Book, 36 Europe, 17 Canada, 25 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - EQ 150MG BASE, TABLET;ORAL - EQ 75MG BASE, TABLET;ORAL - EQ 100MG BASE, CAPSULE;ORAL - EQ 100MG BASE, CAPSULE;ORAL - EQ 50MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE, DELAYED RELEASE;ORAL - EQ 100MG BASE, CAPSULE, DELAYED RELEASE;ORAL - EQ 75MG BASE, SYSTEM, EXTENDED RELEASE;PERIODONTAL - 50MG, TABLET, DELAYED RELEASE;ORAL - EQ 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, DELAYED RELEASE;ORAL - EQ 120MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, DELAYED RELEASE;ORAL - EQ 150MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, DELAYED RELEASE;ORAL - EQ 200MG BASE, TABLET, DELAYED RELEASE;ORAL - EQ 50MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, DELAYED RELEASE;ORAL - EQ 60MG BASE, TABLET, DELAYED RELEASE;ORAL - EQ 75MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, DELAYED RELEASE;ORAL - EQ 80MG BASE

RELATED EXCIPIENT COMPANIES

2 EUROAPI, 3 Rochem International Inc, 18 SPI Pharma, 8 Boai NKY Pharmaceuticals Ltd, 6 Gangwal Healthcare, 7 Nanjing Well Pharmaceutical, 2 Pfanstiehl, 6 Kirsch Pharma, 2 Cerata Pharmaceuticals LLP, 2 Dr. Paul Lohmann GmbH & Co. KGaA, 4 ACG Worldwide, 12 Actylis, 2 Aeon Procare, 1 Alcedo Pharmachem, 9 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 3 Ashland, 33 BASF, 1 CD Formulation, 1 Clariant, 11 Corel Pharma Chem, 7 DFE Pharma, 1 Esteem Industries, 3 Finar, 12 Gangwal Chemicals, 1 Gloria Interchem, 6 Ideal Cures, 5 Ingredion Pharma Solutions, 1 JJ Chemicals, 27 Kerry, 4 Keval Exports, 5 Kima Chemical, 6 Lonza Capsugel, 22 Microlex e.U, 1 Nanjing Bold Chemical, 1 Neelkanth MineChem, 2 Nitika Pharmaceutical Specialities, 2 Nomisma Healthcare, 4 Novo Excipients, 4 Pharmatrans-Sanaq, 8 Pluviaendo, 4 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 2 Qualicaps, 29 Roquette, 14 Seppic, 8 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 2 Shijiazhuang Huaxu Pharmaceutical, 11 Sigachi Industries, 4 Silverline Chemicals, 4 The Dow Chemical Company, 2 Ulanqab Kema New Material, 1 Valens Pharmachem, 4 Vasa Pharmachem, 1 Vertellus, 1 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

82 Fillers, Diluents & Binders, 58 Coating Systems & Additives, 44 Disintegrants & Superdisintegrants, 44 Direct Compression, 38 Thickeners and Stabilizers, 38 Granulation, 32 Parenteral, 31 Solubilizers, 29 Controlled & Modified Release, 27 Film Formers & Plasticizers, 25 Taste Masking, 22 Lubricants & Glidants, 21 Chewable & Orodispersible Aids, 21 Topical, 16 Co-Processed Excipients, 9 Empty Capsules, 9 Emulsifying Agents, 8 API Stability Enhancers, 7 Rheology Modifiers, 6 Surfactant & Foaming Agents, 4 Vegetarian Capsules, 2 Coloring Agents, 1 Soft Gelatin

DIGITAL CONTENT

1 Data Compilation #PharmaFlow, 55 News #PharmaBuzz

GLOBAL SALES INFORMATION

38 US Medicaid Prescriptions, 18 Regulatory FDF Prices

MARKET PLACE

78 APIs, 1 FDF Dossiers

PATENTS & EXCLUSIVITIES

14 US Patents

14 US Patents

REF. STANDARDS & IMPURITIES

2 EDQM, 1 Others

$ Xls download

Filters

Last Updated on PharmaCompass	Virtual Booth	Country	Registrant Name	Registration No.	Compound	Registration Date	Manufacturer	Manufacturer's Country	Manufacturer's Address
31/03/2026	Yancheng Suhai Pharmaceutical Co	China	Sam-O Pharmaceutical Co., Ltd.	20110630-101-F-59-02	Doxycycline Hyclate	2011-06-30	Yancheng Suhai Pharmaceutical Co., Ltd	China	No. 92 E.Jiankang Road, Dafeng City, Jiangsu, China
31/03/2026	Yancheng Suhai Pharmaceutical Co	China	Sam-O Pharmaceutical Co., Ltd.	20220527-101-F-98-05	Doxycycline Hyclate	2022-05-27	Yancheng Suhai Pharmaceutical Co.,Ltd	China	Huafeng Industrial Park, Dafeng Port Economic Development Zone, Dafeng District, Yancheng City, Jiangsu Province, China

Privacy policy
Terms and conditions
Disclaimers
Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

Roximycin

Roximycin

ACCESS ALL DATA

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

45 API Suppliers

21 USDMF

11 CEP/COS

1 JDMF

2 EU WC

2 KDMF

13 NDC API

1 VMF

20 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

44 Drugs in Development

FINISHED DOSAGE FORMULATIONS

269 FDF Dossiers

191 FDA Orange Book

36 Europe

17 Canada

25 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - EQ 150MG BASE

TABLET;ORAL - EQ 75MG BASE

TABLET;ORAL - EQ 100MG BASE

CAPSULE;ORAL - EQ 100MG BASE

CAPSULE;ORAL - EQ 50MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

CAPSULE, DELAYED RELEASE;ORAL - EQ 100MG BASE

CAPSULE, DELAYED RELEASE;ORAL - EQ 75MG BASE

SYSTEM, EXTENDED RELEASE;PERIODONTAL - 50MG

TABLET, DELAYED RELEASE;ORAL - EQ 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET, DELAYED RELEASE;ORAL - EQ 120MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET, DELAYED RELEASE;ORAL - EQ 150MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET, DELAYED RELEASE;ORAL - EQ 200MG BASE

TABLET, DELAYED RELEASE;ORAL - EQ 50MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET, DELAYED RELEASE;ORAL - EQ 60MG BASE

TABLET, DELAYED RELEASE;ORAL - EQ 75MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET, DELAYED RELEASE;ORAL - EQ 80MG BASE

RELATED EXCIPIENT COMPANIES

2 EUROAPI

3 Rochem International Inc

18 SPI Pharma

8 Boai NKY Pharmaceuticals Ltd

6 Gangwal Healthcare

7 Nanjing Well Pharmaceutical

2 Pfanstiehl

6 Kirsch Pharma

2 Cerata Pharmaceuticals LLP

2 Dr. Paul Lohmann GmbH & Co. KGaA

4 ACG Worldwide

12 Actylis

2 Aeon Procare

1 Alcedo Pharmachem

9 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

3 Ashland

33 BASF

1 CD Formulation

1 Clariant

11 Corel Pharma Chem

7 DFE Pharma

1 Esteem Industries

3 Finar

12 Gangwal Chemicals

1 Gloria Interchem

6 Ideal Cures

5 Ingredion Pharma Solutions

1 JJ Chemicals

27 Kerry

4 Keval Exports

5 Kima Chemical

6 Lonza Capsugel

22 Microlex e.U

1 Nanjing Bold Chemical

1 Neelkanth MineChem

2 Nitika Pharmaceutical Specialities

2 Nomisma Healthcare

4 Novo Excipients

CAPSULE;ORAL - EQ 50MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET, DELAYED RELEASE;ORAL - EQ 100MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET, DELAYED RELEASE;ORAL - EQ 120MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET, DELAYED RELEASE;ORAL - EQ 150MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET, DELAYED RELEASE;ORAL - EQ 50MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET, DELAYED RELEASE;ORAL - EQ 75MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons